

Clinical Study on TSE in Equine Sarcoid Management to be presented at the upcoming ECVS Meeting

Scandinavian ChemoTech today announced that a clinical study conducted by Prof. Cathrine T. Fjordbakk, DVM, PhD, Diplomate ECVS, Diplomate ECVSMR, Professor in Equine Surgery at the Norwegian University of Life Sciences (NMBU), will be presented at the annual scientific meeting of the European College of Veterinary Surgeons (ECVS), in Liverpool, July 2026. The study evaluates the clinical use of Tumour Specific Electroporation™ (TSE) within the vetIQure™ platform for equine sarcoid management.

Presentation at this conference, which is the largest scientific veterinary speciality conference in Europe, supports growing scientific interest in Tumour Specific Electroporation™ as an innovative modality in equine sarcoid management. Details regarding case selection, treatment protocols, and outcomes including long-term follow up (> 8 months) will be presented.

Prof. Fjordbakk commented: *"I am honored to have been given the opportunity to present my findings on the management of equine sarcoids using Tumour Specific Electroporation therapy. Having treated sarcoids with this modality for more than 1.5 years, I value TSE as an important addition to the therapeutic options available in clinical practice. I am happy to continue working with this therapy and look forward to sharing further scientific insights with the community."*

Additional scientific discussion is planned in connection with the 35th Annual Scientific Meeting of the European College of Veterinary Surgeons (ECVS), taking place 9–11 July 2026 in Liverpool, United Kingdom, at the ACC Arena and Convention Centre Liverpool - one of Europe's leading veterinary surgical congresses gathering specialists, researchers, and clinical leaders from across the world.

VQ Animal Care remains committed to supporting evidence-based innovation in veterinary medicine and advancing responsible clinical research in collaboration with academic and clinical partners.

VQ Animal Care's Tumor-Specific Electroporation (TSE) technology provides several important advantages for treating equine tumors and sarcoids:

- Often performed **without general anesthesia**, reducing risk and improving safety.
- Tissue-sparing and **minimally destructive**, resulting in less scarring and better cosmetic and functional outcomes.
- **Lower stress for horses** thanks to shorter, less invasive procedures and fast recovery.

- More cost-efficient for owners, with fewer resources needed and lower overall treatment costs.
- **Accessible in a wide range of clinical settings**, as many treatments can be performed with the horse standing under light sedation.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-02-2026 20:50 CET.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye Sweden AB

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm. Read more at: www.chemotech.se.